Flibanserin - Sprout Pharmaceuticals
Alternative Names: Addyi; BIMT 17; BIMT 17 BS; Girosa®Latest Information Update: 31 Jul 2025
At a glance
- Originator Boehringer Ingelheim
- Developer Boehringer Ingelheim; Sprout Pharmaceuticals
- Class Antidepressants; Anxiolytics; Benzimidazoles; Ketones; Small molecules
- Mechanism of Action 5-HT1A serotonin receptor agonists; Serotonin 5-HT2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Female sexual dysfunction
- Discontinued Major depressive disorder
Most Recent Events
- 24 Jul 2025 Flibanserin receives priority review status for Female sexual dysfunction in postmenopausal women in USA
- 24 Jul 2025 Health Canada approves flibanserin for Female sexual dysfunction in postmenopausal women in Canada, before July 2025
- 16 Sep 2020 Launched for Female sexual dysfunction in Canada (PO)